^
    Back
    Association details:
    Biomarker:PTPN11 mutation + KRAS wild-type
    Cancer:Non Small Cell Lung Cancer
    Drug:Aliqopa (copanlisib) (PIK3CA inhibitor, PI3Kδ inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Int J Mol Sci
    Title:

    Protein Tyrosine Phosphatase Non-Receptor 11 ( PTPN11/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)

    Published date:
    07/14/2023
    Excerpt:
    NCI-H661 cells (PTPN11-mutated, KRAS-wild type) were significantly more sensitive to growth inhibition by the PI3K inhibitor copanlisib (IC50: 13.9 ± 4.7 nM) compared to NCI-H1703 (PTPN11/KRAS-wild type) cells (IC50: >10,000 nM).
    DOI:
    10.3390/ijms241310545